⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337497 | 0.67 | — | — | |
| SCHEMBL337498 | 0.67 | — | — | |
| SCHEMBL3270492 | 0.64 | — | — | |
| SCHEMBL1632136 | 0.61 | — | — | |
| SCHEMBL3069183 | 0.61 | — | — | |
| SCHEMBL1632138 | 0.61 | — | — | |
| SCHEMBL11819079 | 0.61 | — | — | |
| SCHEMBL8337792 | 0.57 | — | — | |
| SCHEMBL7047663 | 0.57 | — | — | |
| SCHEMBL20205537 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | claimed |
| US-20180153889-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | BACH PHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9732043-B2 | Process for preparing 5-amino-2,3-dihydrophthalazine-1,4-dione monosodium salt | BACH PHARMA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160237039-A1 | PHARMACEUTICAL GRADE PHTHALAZINEDIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Occhiuti & Rohlicek LLP | 2016-08-18 | — | — | US | disclosed |
| EP-2393361-A1 | PHARMACEUTICAL GRADE PHTHALAZINEDIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Bach Pharma, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-2346522-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND NRF2 TRANSCRIPTION FACTORS | Bach Pharma, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100222584-A1 | PHARMACEUTICAL GRADE PHTHALAZINEDIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BACH PHARMA, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010091257-A1 | PHARMACEUTICAL GRADE PHTHALAZINEDIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BACH PHARMA, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100086531-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND Nrf2 TRANSCRIPTION FACTORS | BACH PHARMA INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010036711-A1 | METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND NRF2 TRANSCRIPTION FACTORS | BACH PHARMA INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7282590-B2 | Selectively target tumor cells with highly potent cytotoxic drugs at a drug release rate that is effective for the destruction and/or inhibition of tumor cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-10-16 | — | — | US | disclosed |
| US-20050288291-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050232928-A1 | Drug conjugates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-20 | — | — | US | disclosed |